Seoul National University

Korea Research Institute of Bioscience and Biotechnology

Ewha University-industry Collaboration Foundation

University of Ulsan Foundation for Industry Cooperation

The Asan Foundation

Institut Pasteur Korea

Edisbiotech Co., Ltd.

The Asan Foundation, University of Ulsan Foundation for Industry Cooperation

Hyori Kim

Junho Chung

Ki-Hyun Kim

Soohyun Kim

Hwa Kyoung Lee

Junyeong Jin

Won Jun Yang

Ji Eun Kim

Jeong Hun Kim

Jinhee Kim

Ji Eun Lee

Jong Bae Park

Dong Hyun Jo

Su Ui Lee

In Pyo Choi

Eugene C Yi

Seung-Jae Myung

Hyung-Bae Park

Sooyun Lee

Eun-Ju Do

Yeong Hui Cho

Jayoung Kang

Seungtaek Kim

Hye-Nam Son

A-Neum Lee

Suree Kim

Dongmin Kang

Dobeen Hwang

Tae-Don Kim

Gunwoo Park

Yumi Oh

Kyungho Choi

Myoung-don Oh

Meehyun Ko

Ji-Young Min

Wan Beom Park

The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.

Monoclonal antibody specifically binding to CCSP-2 and use thereof

The present invention relates to an antibody against a PDGF receptor, an antibody-drug conjugate in which a chemotherapeutic agent is conjugated to the antibody against PDGF receptor, and a use of prevention or treatment of ocular neovascular diseases.

PDGF receptor antibody and use thereof

The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis.

Anti-ROS1 antibody and use thereof

Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

Natural killer cell expressing anti-cotinine chimeric antigen receptor

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof

The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.

Anti-C5 antibodies and methods of treating complement-related diseases

The present invention relates to an antibody drug conjugate using a bispecific antibody and its use. The antibody drug conjugate of the present invention can easily form a conjugate of an antibody and a drug without a multistep synthetic process though binding of a conjugate of a bivalent cotinine-peptide and a drug, and an anti-cotinine single chain variable fragment. In addition, the antibody drug conjugate can effectively deliver a drug to a target to which the antibody binds specifically, and can enhance a half-life of a drug in the body, thereby improving a therapeutic effect.

Antibody drug conjugate platform using bispecific antibody

The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.

Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus and use for same

Growing community of inventors

Seoul, South Korea

Hyori Kim